BACKGROUND: Although orthostatic hypotension (OH) is recognized as one of the main non-motor symptoms of Parkinson's disease (PD), there is inconsistent evidence about the prevalence of OH in PD. To estimate the prevalence of OH in PD more precisely we conducted a systematic review of the literature. METHODS: From PubMed and Embase searches with predefined inclusion criteria, we identified studies published up till December 2009. Prevalence numbers from studies were pooled using a non-linear random-effects meta-analysis. RESULTS: We found 25 studies from which the prevalence of OH could be calculated. The pooled estimate of the point prevalence of OH in PD was 30.1% (95% CI: 22.9% to 38.4%). We found a large statistical heterogeneity between studies which could not be reduced by several subgroup analyses. CONCLUSIONS: The estimated prevalence of OH in PD is 30%. However, due to the large heterogeneity between studies this pooled estimate should be interpreted with caution. More data from unselected population-based cohorts are needed.
BACKGROUND: Although orthostatic hypotension (OH) is recognized as one of the main non-motor symptoms of Parkinson's disease (PD), there is inconsistent evidence about the prevalence of OH in PD. To estimate the prevalence of OH in PD more precisely we conducted a systematic review of the literature. METHODS: From PubMed and Embase searches with predefined inclusion criteria, we identified studies published up till December 2009. Prevalence numbers from studies were pooled using a non-linear random-effects meta-analysis. RESULTS: We found 25 studies from which the prevalence of OH could be calculated. The pooled estimate of the point prevalence of OH in PD was 30.1% (95% CI: 22.9% to 38.4%). We found a large statistical heterogeneity between studies which could not be reduced by several subgroup analyses. CONCLUSIONS: The estimated prevalence of OH in PD is 30%. However, due to the large heterogeneity between studies this pooled estimate should be interpreted with caution. More data from unselected population-based cohorts are needed.
Authors: C Peralta; M Stampfer-Kountchev; E Karner; M Köllensperger; F Geser; E Wolf; K Seppi; T Benke; W Poewe; G K Wenning Journal: J Neural Transm (Vienna) Date: 2007-01-03 Impact factor: 3.575
Authors: J M Senard; S Raï; M Lapeyre-Mestre; C Brefel; O Rascol; A Rascol; J L Montastruc Journal: J Neurol Neurosurg Psychiatry Date: 1997-11 Impact factor: 10.154
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: Maarit Matinolli; Juha T Korpelainen; Raija Korpelainen; Kyösti A Sotaniemi; Vilho V Myllylä Journal: Mov Disord Date: 2009-04-15 Impact factor: 10.338
Authors: David S Goldstein; Courtney Holmes; Oladi Bentho; Takuya Sato; Jeffrey Moak; Yehonatan Sharabi; Richard Imrich; Shielah Conant; Basil A Eldadah Journal: Parkinsonism Relat Disord Date: 2008-03-05 Impact factor: 4.891
Authors: Tonya N Taylor; Shawn P Alter; Minzheng Wang; David S Goldstein; Gary W Miller Journal: Neuropharmacology Date: 2013-09-08 Impact factor: 5.250
Authors: T Pérez; B Tijero; I Gabilondo; A Luna; V Llorens; K Berganzo; M Acera; A Gonzalez; A Sanchez-Ferro; E Lezcano; J J Zarranz; J C Gómez-Esteban Journal: J Hum Hypertens Date: 2015-01-29 Impact factor: 3.012